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Context
In 2011, the World Health Organization
(WHO) Essential Medicines Programme
published a list of ‘‘priority medicines’’ they
considered essential for countries to achieve
the Millennium Development Goals in
child and maternal health [1]. This list
was a subset of the model Essential
Medicines List (EML), produced every 2
years by theWHO, which selects medicines
on the basis of public health relevance,
comparative effectiveness, safety, cost, and
regulatory status [2].
The WHO model EML is adapted for
use in Ghana by the Ghana National
Drugs Programme of the Ministry of
Health (MOH), and access to essential
medicines is now largely financed through
the National Health Insurance Scheme
(NHIS). This scheme was established by
the government of Ghana in 2003, and
covers over 60% of the population [3].
Membership of the NHIS is through
annual subscription, but free of charge to
those under 18, over 70, pregnant, or the
very poor, and members may access care
through accredited public and private
health care providers [4].
Following publication of the 2011
model EML it was noted that five of the
priority paediatric medicines were not
included in the 2010 Ghana EML: oral
zinc sulphate for acute diarrhoea, inject-
able artesunate for severe malaria, topical
chlorhexidine for preventing neonatal
cord sepsis, dispersible oral amoxicillin
for community acquired pneumonia, and
oral and injectable caffeine citrate for
neonatal apnoea [5].
Before adopting these medicines, the
Ghana National Drugs Programme
(GNDP) wanted to review the evidence
base and how it applied to Ghana, using a
transparent and evidence-informed ap-
proach, which further considered the local
priorities, feasibility, and resource impli-
cations. In this paper we report on how
the GNDP did this, and the difficulties
experienced when interpreting and apply-
ing global recommendations to a national
context.
About This Project
The National Drugs Programme first
prepared concise evidence summaries for
each of the five WHO ‘‘priority’’ medi-
cines. These five summaries were then
used by the Ghana ‘‘Standard Treatment
Guidelines’’ expert review committee in
November 2011 (with representation from
the NHIS and GNDP), to facilitate an
open and informed discussion.
Training in the retrieval, appraisal, and
interpretation of systematic reviews was
provided for a selected team of Ministry of
Health staff by specialists from the Liver-
pool School of Tropical Medicine. These
staff then wrote the summaries, following a
structure based on the work of the
SUPPORT collaboration, summarising
existing systematic reviews, rather than
conducting new reviews [6]. The summa-
ries addressed four main questions:
N What are the benefits and harms of
[drug name]?
N What would be the public health
impact of introducing [drug name] in
Ghana?
N What are the resource implications to
the country of introducing it?
N Is introduction currently feasible and
acceptable in Ghana?
For evidence of benefits and harms
participants searched the Cochrane Li-
brary and PubMed for existing systematic
reviews. When more than one systematic
review was found, the most reliable review
was chosen on the basis of an evaluation of
the search strategy and methods. When
the most recent review was more than 2
years old an additional PubMed search
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was conducted for recently published
randomized controlled trials. Confidence
in the methods of systematic reviews was
appraised using the AMSTAR checklist
[7], and confidence in the results was
appraised using the GRADE approach for
assessing the quality of evidence [8]. For
evidence on cost-effectiveness, participants
reviewed the NHS Economics Database
for economic evaluations relevant to each
medicine, and appraised the methods
using the CHEC-list [9]. The applicability
of the systematic reviews and economic
evaluations to Ghana was assessed follow-
ing the guidance of the SUPPORT
collaboration [10].
The potential public health impact of
introducing eachmedicine was estimated by
applying the relative mortality reductions
from trial data to the best available national
statistics for disease burden. A commentary
on the costs and feasibility of introduction
was prepared by reviewing international
price guides for potential suppliers [11,12],
comparing the new drug price to the
current alternative, and identifying any
additional system or educational require-
ments for successful introduction [13].
A brief summary of the findings of each
evidence summary is presented in Table 1.
The full summaries are available as on-line
supplements to this paper, and may pro-
vide useful templates for other countries.
Our Experience
Applying global recommendations to
Ghana was not straightforward for any of
the five medicines, regardless of the
presence of high quality evidence of
important clinical benefits (Table 2). We
have summarised the four key factors that
generated debate and uncertainty in the
committee, and tempered automatic adop-
tion of the five medicines.
1. Applicability: Few of the Trials
Were Conducted in Africa
The applicability of the evidence base
for both zinc sulphate (for diarrhoea) and
chlorhexidine 4% solution (for cord care)
to Ghana was limited, as the majority of
available data came from Asian countries,
where the effects could reasonably be
expected to be different.
Zinc sulphate is recommended by the
WHO as an adjunct to oral rehydration
therapy for children with acute diarrhoea
[14]. However, of the 44 trials included in
the Cochrane review of zinc therapy, only
two were conducted in Africa, neither of
which demonstrated a clinical benefit [15].
In Asia, zinc appeared to shorten the
duration of diarrhoea but with significant
heterogeneity in the size of this effect. Sub-
group analyses suggests that the effect is
largest in children aged greater than 6
months with signs of moderate malnutri-
tion, and as a nutritional intervention this
has a logical consistency. It was on this
basis that the committee decided to
introduce Zinc sulphate in Ghana, where
malnutrition in some rural areas is above
30% [16].
2. Applicability: The Control Groups
Used in Trials Differ from Current
Practice
The applicability of the global evidence
base for chlorhexidine, and artesunate
(for severe malaria), was limited because
the control groups used in the primary
research were different to current practice
in Ghana.
Chlorhexidine was included on the
WHO list of priority medicines for appli-
cation to the umbilical stump to prevent
neonatal sepsis [1]. The published eviden-
ce evaluating chlorhexidine (available in
2011), was limited to a single large trial
from Nepal [17]. This trial had two control
interventions: soap and water and dry cord
care, whereas current practice in Ghana
most commonly involves the application of
alcohol: an intervention that has itself
never been evaluated. In addition, the
intervention in the Nepalese efficacy trial
was delivered via an intensive regimen of
post-natal home visits, which would be
neither feasible nor affordable in Ghana.
As a consequence, the committee consid-
ered the evidence insufficient to introduce
chlorhexidine nationwide at that time.
Similarly, most trials evaluating artesu-
nate have compared it to quinine, but in
Ghana, as in many sub-Saharan countries,
injectable artemether has become widely
popular due to the ease of intra-muscular
administration. Only a single trial in adults
from Asia has directly compared artesu-
nate with artemether and the result did
not reach statistical significance [18].
3. Cost and Cost-Effectiveness: Data
Not Available
The cost of introducing each medicine
was important for the committee, but
none of the WHO documents recom-
mending these five medicines included
advice or guidance on costs [1,14,19–21].
Searches of the NHS Economics Evalua-
tions Database found two economic evalua-
tions of artesunate versus quinine [22,23].
One of these presented a cost-benefit analysis
from three African study sites involved in a
large efficacy trial [24], and found artesunate
to be highly cost-effective in comparison to
quinine (an estimated US$123 per additional
life saved) [22].
Only one further cost-effectiveness evalu-
ation was available, for zinc sulphate, which
had limited applicability to Ghana [25]. This
evaluation concluded that the additional costs
of zinc sulphate were offset by gains in the
mothers’ time and productivity through
reduced illness duration. From a health
providers’ perspective, although a course of
zinc is relatively cheap (US$0.28), the burden
of diarrhoeal disease is such that drug costs
may be substantial.
4. Feasibility: Limitations with the
Current Supply Chain
The committee was concerned about
the harmful effects of changing national
Summary Points
N This paper reports the experience of the Ghana National Drugs Programme as
they reviewed the international evidence base for five priority paediatric
medicines.
N Applying the global recommendations to Ghana was not straightforward for
any of the five medicines, regardless of the presence of high quality evidence of
important clinical benefits.
N Four main factors generated debate and uncertainty in the committee: (1)
effect unproven in African settings; (2) control group in trials not consistent
with current practice; (3) little evidence on cost and cost effectiveness; and (4)
limited supply chain.
N This project demonstrates why global recommendations should be presented
alongside transparent descriptions of the evidence base, allowing policy groups
to identify where, when, and how the interventions have been evaluated, and
any factors limiting applicability.
N As many policy questions are relevant across sub-Saharan Africa, and policy
makers are likely to encounter similar problems, we encourage regional
collaboration on health technology assessment, and sharing of information and
resources.
PLOS Medicine | www.plosmedicine.org 2 May 2013 | Volume 10 | Issue 5 | e1001449
T
a
b
le
1
.
Su
m
m
ar
y
o
f
G
h
an
a
e
vi
d
e
n
ce
su
m
m
ar
ie
s.
P
ri
o
ri
ty
M
e
d
ic
in
e
(F
o
rm
u
la
ti
o
n
)
B
e
n
e
fi
ts
H
a
rm
s
P
o
te
n
ti
a
l
P
u
b
li
c
H
e
a
lt
h
Im
p
a
ct
F
e
a
si
b
il
it
y
R
e
so
u
rc
e
Im
p
li
ca
ti
o
n
s
Z
in
c
su
lp
h
a
te
(S
co
re
d
d
is
p
e
rs
ib
le
ta
b
le
ts
2
0
m
g
)
C
o
m
p
ar
e
d
to
p
la
ce
b
o
:
N
M
ay
sh
o
rt
e
n
th
e
d
u
ra
ti
o
n
o
f
d
ia
rr
h
o
e
a
in
ch
ild
re
n
ag
e
d
.
6
m
o
n
th
s
(l
o
w
q
u
a
lit
y
ev
id
en
ce
),
N
P
ro
b
ab
ly
h
as
a
la
rg
e
r
e
ff
e
ct
in
ch
ild
re
n
w
it
h
m
al
n
u
tr
it
io
n
(m
o
d
er
a
te
q
u
a
lit
y
ev
id
en
ce
).
C
o
m
p
ar
e
d
to
p
la
ce
b
o
:
N
M
ay
in
cr
e
as
e
th
e
d
u
ra
ti
o
n
o
f
d
ia
rr
h
o
e
a
In
ch
ild
re
n
ag
e
d
,
6
m
o
n
th
s
(l
o
w
q
u
a
lit
y
ev
id
en
ce
),
N
In
cr
e
as
e
s
vo
m
it
in
g
in
b
o
th
ag
e
g
ro
u
p
s
(h
ig
h
q
u
a
lit
y
ev
id
en
ce
).
A
n
e
ff
e
ct
o
n
ch
ild
m
o
rt
al
it
y
h
as
n
o
t
b
e
e
n
re
lia
b
ly
d
e
m
o
n
st
ra
te
d
Lo
ca
l
m
an
u
fa
ct
u
re
is
n
o
w
in
o
p
e
ra
ti
o
n
A
lt
h
o
u
g
h
a
co
u
rs
e
o
f
zi
n
c
su
lp
h
at
e
is
re
la
ti
ve
ly
ch
e
ap
,
th
e
re
so
u
rc
e
im
p
lic
at
io
n
s
m
ay
b
e
h
ig
h
d
u
e
to
th
e
b
u
rd
e
n
o
f
d
is
e
as
e
.
A
rt
e
su
n
a
te
(6
0
m
g
v
ia
l
fo
r
in
je
ct
io
n
p
lu
s
5
%
so
d
iu
m
b
ic
a
rb
o
n
a
te
b
u
ff
e
r)
C
o
m
p
ar
e
d
to
q
u
in
in
e
:
N
Lo
w
e
rs
m
o
rt
al
it
y
(h
ig
h
q
u
a
lit
y
ev
id
en
ce
)
C
o
m
p
ar
e
d
to
q
u
in
in
e
:
N
Sl
ig
h
tl
y
in
cr
e
as
e
s
n
e
u
ro
lo
g
ic
al
se
q
u
e
la
e
at
h
o
sp
it
al
d
is
ch
ar
g
e
(h
ig
h
q
u
a
lit
y
ev
id
en
ce
),
N
P
ro
b
ab
ly
d
o
e
sn
’t
in
cr
e
as
e
lo
n
g
-t
e
rm
n
e
u
ro
lo
g
ic
al
se
q
u
e
la
e
(m
o
d
er
a
te
q
u
a
lit
y
ev
id
en
ce
).
P
o
te
n
ti
al
to
p
re
ve
n
t
u
p
to
1
,5
0
0
ch
ild
h
o
o
d
d
e
at
h
s
p
e
r
ye
ar
in
G
h
an
a
D
e
p
e
n
d
e
n
t
o
n
id
e
n
ti
fi
ca
ti
o
n
o
f
a
re
lia
b
le
su
p
p
lie
r
C
h
an
g
e
to
ar
te
su
n
at
e
m
ay
co
st
th
e
G
h
an
ai
an
N
at
io
n
al
M
al
ar
ia
P
ro
g
ra
m
m
e
an
ad
d
it
io
n
al
U
S$
1
8
0
,0
0
0
p
e
r
ye
ar
.
C
h
lo
rh
e
x
id
in
e
(4
%
so
lu
ti
o
n
)
C
o
m
p
ar
e
d
to
d
ry
co
rd
ca
re
o
r
so
ap
an
d
w
at
e
r:
N
M
ay
re
d
u
ce
n
e
o
n
at
al
m
o
rt
al
it
y
(l
o
w
q
u
a
lit
y
ev
id
en
ce
),
N
P
ro
b
ab
ly
re
d
u
ce
s
se
ve
re
an
d
m
o
d
e
ra
te
co
rd
in
fe
ct
io
n
s
(m
o
d
er
a
te
q
u
a
lit
y
ev
id
en
ce
).
C
o
m
p
ar
e
d
to
d
ry
co
rd
ca
re
o
r
so
ap
an
d
w
at
e
r:
N
N
o
n
e
kn
o
w
n
P
o
te
n
ti
al
to
p
re
ve
n
t
u
p
to
4
,5
0
0
n
e
o
n
at
al
d
e
at
h
s
p
e
r
ye
ar
in
G
h
an
a
T
o
ac
h
ie
ve
th
e
e
ff
e
ct
se
e
n
in
th
e
tr
ia
l
m
o
th
e
rs
w
e
re
vi
si
te
d
at
h
o
m
e
si
x
ti
m
e
s,
w
h
ic
h
m
ay
n
o
t
b
e
fe
as
ib
le
in
G
h
an
a
N
o
e
co
n
o
m
ic
e
va
lu
at
io
n
s
w
e
re
fo
u
n
d
A
m
o
x
ic
il
li
n
(5
0
0
m
g
/2
5
0
m
g
sc
o
re
d
d
is
p
e
rs
ib
le
ta
b
le
ts
)
C
o
m
p
ar
e
d
to
su
sp
e
n
si
o
n
:
N
Im
p
ro
ve
d
d
o
se
ac
cu
ra
cy
,
N
Lo
n
g
e
r
sh
e
lf
-l
if
e
w
it
h
n
o
n
e
e
d
fo
r
re
fr
ig
e
ra
ti
o
n
,
N
Le
ss
b
u
lk
y
fo
r
tr
an
sp
o
rt
an
d
le
ss
su
sc
e
p
ti
b
le
to
h
ig
h
te
m
p
e
ra
tu
re
s.
C
o
m
p
ar
e
d
to
su
sp
e
n
si
o
n
:
N
N
o
n
e
kn
o
w
n
P
ro
b
ab
ly
m
in
im
al
D
e
p
e
n
d
e
n
t
o
n
id
e
n
ti
fi
ca
ti
o
n
o
f
a
re
lia
b
le
su
p
p
lie
r
C
o
u
ld
re
p
re
se
n
t
a
co
st
-
sa
vi
n
g
d
e
p
e
n
d
an
t
o
n
su
p
p
lie
r
C
a
ff
e
in
e
ci
tr
a
te
(I
n
je
ct
io
n
a
n
d
o
ra
l
so
lu
ti
o
n
2
0
m
g
/m
l;
e
q
u
iv
a
le
n
t
to
1
0
m
g
ca
ff
e
in
e
b
a
se
/m
l)
C
o
m
p
ar
e
d
to
p
la
ce
b
o
:
N
P
ro
b
ab
ly
re
d
u
ce
s
th
e
ri
sk
o
f
d
e
at
h
>
o
r
m
aj
o
r
d
is
ab
ili
ty
b
y
la
te
in
fa
n
cy
(m
o
d
er
a
te
q
u
a
lit
y
ev
id
en
ce
),
N
R
e
d
u
ce
s
th
e
ri
sk
o
f
ch
ro
n
ic
lu
n
g
d
is
e
as
e
(h
ig
h
q
u
a
lit
y
ev
id
en
ce
),
N
P
ro
b
ab
ly
re
d
u
ce
s
th
e
ri
sk
o
f
co
g
n
it
iv
e
d
e
la
y
(m
o
d
er
a
te
q
u
a
lit
y
ev
id
en
ce
).
C
o
m
p
ar
e
d
to
p
la
ce
b
o
/t
h
e
o
p
h
yl
lin
e
:
N
C
af
fe
in
e
p
ro
b
ab
ly
h
as
fe
w
e
r
si
d
e
-e
ff
e
ct
s
th
an
th
e
o
p
h
yl
lin
e
(m
o
d
er
a
te
q
u
a
lit
y
ev
id
en
ce
)
P
re
m
at
u
ri
ty
is
co
n
si
d
e
re
d
th
e
se
co
n
d
m
aj
o
r
ca
u
se
o
f
in
fa
n
t
m
o
rt
al
it
y
in
G
h
an
a,
h
o
w
e
ve
r
re
lia
b
le
e
st
im
at
e
s
o
f
b
u
rd
e
n
o
f
n
e
o
n
at
al
ap
n
o
e
a
w
e
re
u
n
av
ai
la
b
le
T
h
e
re
ar
e
cu
rr
e
n
tl
y
n
o
in
te
rn
at
io
n
al
su
p
p
lie
rs
o
f
a
su
it
ab
le
p
ro
d
u
ct
N
o
p
ri
ce
e
st
im
at
e
s
o
r
e
co
n
o
m
ic
e
va
lu
at
io
n
s
w
e
re
fo
u
n
d
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
m
e
d
.1
0
0
1
4
4
9
.t
0
0
1
PLOS Medicine | www.plosmedicine.org 3 May 2013 | Volume 10 | Issue 5 | e1001449
T
a
b
le
2
.
P
ro
b
le
m
s
ap
p
ly
in
g
th
e
g
lo
b
al
re
co
m
m
e
n
d
at
io
n
s
to
G
h
an
a.
P
ri
o
ri
ty
M
e
d
ic
in
e
C
u
rr
e
n
t
W
H
O
R
e
co
m
m
e
n
d
a
ti
o
n
[S
o
u
rc
e
]
P
ro
b
le
m
s
E
n
co
u
n
te
re
d
in
A
p
p
ly
in
g
th
e
G
lo
b
a
l
E
v
id
e
n
ce
B
a
se
to
G
h
a
n
a
P
a
n
e
l
C
o
n
si
d
e
ra
ti
o
n
a
n
d
D
e
ci
si
o
n
Z
in
c
su
lp
h
a
te
(S
co
re
d
d
is
p
e
rs
ib
le
ta
b
le
ts
2
0
m
g
)
N
Fo
r
ch
ild
re
n
ag
e
d
,
1
ye
ar
s
w
it
h
ac
u
te
d
ia
rr
h
o
e
a:
1
0
m
g
o
n
ce
d
ai
ly
fo
r
1
4
d
ay
s
N
Fo
r
ch
ild
re
n
ag
e
.
1
ye
ar
s
w
it
h
ac
u
te
d
ia
rr
h
o
e
a:
2
0
m
g
o
n
ce
d
ai
ly
fo
r
1
4
d
ay
s
[1
4
].
N
M
o
st
tr
ia
l
re
se
ar
ch
is
fr
o
m
A
si
an
co
u
n
tr
ie
s
at
h
ig
h
ri
sk
o
f
zi
n
c
d
e
fi
ci
e
n
cy
.
N
N
o
e
ff
e
ct
h
as
b
e
e
n
se
e
n
in
A
fr
ic
an
tr
ia
ls
fr
o
m
se
tt
in
g
s
at
m
o
d
e
ra
te
ri
sk
o
f
zi
n
c
d
e
fi
ci
e
n
cy
.
N
T
h
e
re
is
si
g
n
if
ic
an
t
h
e
te
ro
g
e
n
e
it
y
in
th
e
m
ag
n
it
u
d
e
o
f
th
e
b
e
n
e
fi
t
o
f
su
p
p
le
m
e
n
ta
ti
o
n
.
N
T
h
e
e
ff
e
ct
is
la
rg
e
st
an
d
m
o
st
co
n
si
st
e
n
t
in
ch
ild
re
n
w
it
h
si
g
n
s
o
f
m
o
d
e
ra
te
m
al
n
u
tr
it
io
n
.
N
D
is
p
e
rs
ib
le
zi
n
c
ta
b
le
ts
w
e
re
ad
d
e
d
to
th
e
EM
L
o
n
th
e
b
as
is
o
f
ve
ry
h
ig
h
le
ve
ls
o
f
m
al
n
u
tr
it
io
n
am
o
n
g
ch
ild
re
n
ag
e
d
,
5
ye
ar
s
in
n
o
rt
h
e
rn
an
d
ru
ra
l
ar
e
as
.
A
rt
e
su
n
a
te
(6
0
m
g
vi
al
fo
r
in
je
ct
io
n
p
lu
s
5
%
so
d
iu
m
b
ic
ar
b
o
n
at
e
b
u
ff
e
r)
N
Fo
r
al
l
ch
ild
re
n
u
n
d
e
r
5
w
it
h
se
ve
re
m
al
ar
ia
:
2
.4
m
g
/k
g
o
n
ad
m
is
si
o
n
,
at
1
2
h
o
u
rs
,
2
4
h
o
u
rs
,
an
d
th
e
n
d
ai
ly
u
n
ti
l
o
ra
l
th
e
ra
p
y
to
le
ra
te
d
[1
9
].
N
T
h
e
e
vi
d
e
n
ce
o
f
th
e
su
p
e
ri
o
ri
ty
o
f
ar
te
su
n
at
e
o
ve
r
q
u
in
in
e
is
w
e
ll
d
o
cu
m
e
n
te
d
b
u
t
ar
te
m
e
th
e
r
is
cu
rr
e
n
tl
y
o
n
e
o
f
th
e
m
o
st
w
id
e
ly
u
se
d
in
je
ct
ab
le
an
ti
m
al
ar
ia
ls
in
G
h
an
a.
N
T
h
e
W
H
O
M
al
ar
ia
T
re
at
m
e
n
t
G
u
id
e
lin
e
d
o
e
s
n
o
t
co
n
si
d
e
r
o
r
o
ff
e
r
ad
vi
ce
o
n
th
e
co
st
o
r
fe
as
ib
ili
ty
o
f
in
tr
o
d
u
ci
n
g
ar
te
su
n
at
e
.
N
G
h
an
ai
an
e
st
im
at
e
s
o
f
in
ci
d
e
n
ce
an
d
m
o
rt
al
it
y
o
f
se
ve
re
m
al
ar
ia
ap
p
e
ar
u
n
re
lia
b
le
,
w
h
ic
h
in
tu
rn
m
ak
e
s
e
st
im
at
e
s
o
f
th
e
p
o
te
n
ti
al
p
u
b
lic
h
e
al
th
im
p
ac
t
an
d
co
st
u
n
re
lia
b
le
.
N
A
rt
e
su
n
at
e
an
d
ar
te
m
e
th
e
r
w
e
re
co
m
p
ar
e
d
in
d
ir
e
ct
ly
b
y
n
o
ti
n
g
th
at
ar
te
m
e
th
e
r
ap
p
e
ar
s
e
q
u
iv
al
e
n
t
to
q
u
in
in
e
,
an
d
q
u
in
in
e
is
in
fe
ri
o
r
to
ar
te
su
n
at
e
.
N
A
rt
e
su
n
at
e
w
as
ad
d
e
d
to
G
h
an
a
EM
L
an
d
fo
r
d
is
cu
ss
io
n
w
it
h
G
h
an
a
M
al
ar
ia
C
o
n
tr
o
l
P
ro
g
ra
m
m
e
fo
r
co
n
si
d
e
ra
ti
o
n
as
fi
rs
t
lin
e
tr
e
at
m
e
n
t
in
G
h
an
a.
N
T
h
e
ch
an
g
e
to
ar
te
su
n
at
e
w
ill
n
o
t
b
e
m
ad
e
u
n
ti
l
a
re
lia
b
le
su
p
p
ly
o
f
a
h
ig
h
q
u
al
it
y,
af
fo
rd
ab
le
p
ro
d
u
ct
is
as
su
re
d
.
C
h
lo
rh
e
x
id
in
e
(4
%
so
lu
ti
o
n
)
N
Fo
r
al
l
n
e
o
n
at
e
s:
A
p
p
ly
d
ai
ly
to
u
m
b
ili
ca
l
st
u
m
p
[1
].
N
T
h
e
o
n
ly
av
ai
la
b
le
e
vi
d
e
n
ce
fo
r
ch
lo
rh
e
xi
d
in
e
is
fr
o
m
a
si
n
g
le
tr
ia
l
in
N
e
p
al
.
N
T
h
is
tr
ia
l
in
vo
lv
e
d
in
te
n
si
ve
h
o
m
e
vi
si
ts
d
u
ri
n
g
th
e
p
o
st
-n
at
al
p
e
ri
o
d
w
h
ic
h
m
ay
n
o
t
b
e
fe
as
ib
le
in
G
h
an
a.
N
T
h
e
co
rd
ca
re
re
ce
iv
e
d
b
y
th
e
co
n
tr
o
l
g
ro
u
p
s
in
th
e
si
n
g
le
tr
ia
l
is
d
if
fe
re
n
t
to
cu
rr
e
n
t
p
ra
ct
ic
e
in
G
h
an
a.
N
T
h
e
p
an
e
l
co
n
si
d
e
re
d
th
e
e
vi
d
e
n
ce
in
ad
e
q
u
at
e
to
ad
o
p
t
ch
lo
rh
e
xi
d
in
e
n
at
io
n
al
ly
.
N
La
rg
e
-s
ca
le
e
ff
e
ct
iv
e
n
e
ss
st
u
d
ie
s
ar
e
u
n
d
e
rw
ay
in
A
fr
ic
a
an
d
ch
lo
rh
e
xi
d
in
e
w
ill
b
e
re
vi
e
w
e
d
ag
ai
n
o
n
ce
th
e
se
re
su
lt
s
ar
e
av
ai
la
b
le
.
A
m
o
x
ic
il
li
n
(5
0
0
m
g
/
2
5
0
m
g
sc
o
re
d
d
is
p
e
rs
ib
le
ta
b
le
ts
)
N
Fo
r
al
l
ch
ild
re
n
u
n
d
e
r
5
w
it
h
co
m
m
u
n
it
y
ac
q
u
ir
e
d
p
n
e
u
m
o
n
ia
:
2
5
m
g
/k
g
tw
ic
e
d
ai
ly
fo
r
3
to
5
d
ay
s
[2
0
].
N
W
h
ile
d
is
p
e
rs
ib
le
ta
b
le
ts
o
ff
e
r
cl
e
ar
lo
g
is
ti
ca
l
b
e
n
e
fi
ts
o
ve
r
su
sp
e
n
si
o
n
s,
th
e
W
H
O
re
co
m
m
e
n
d
at
io
n
al
so
in
cl
u
d
e
s
a
ch
an
g
e
in
fr
e
q
u
e
n
cy
an
d
d
u
ra
ti
o
n
o
f
tr
e
at
m
e
n
t,
w
it
h
lit
tl
e
e
vi
d
e
n
ce
to
su
p
p
o
rt
th
is
.
N
T
h
e
p
an
e
l
ag
re
e
d
th
at
d
is
p
e
rs
ib
le
ta
b
le
ts
(a
lr
e
ad
y
in
u
se
as
an
ti
m
al
ar
ia
ls
)
h
av
e
p
ro
g
ra
m
m
at
ic
an
d
co
st
ad
va
n
ta
g
e
s
o
ve
r
su
sp
e
n
si
o
n
s.
N
D
is
p
e
rs
ib
le
am
o
xi
ci
lli
n
w
as
ad
d
e
d
to
th
e
EM
L.
N
T
h
e
sh
o
rt
e
n
e
d
re
g
im
e
n
w
as
n
o
t
ad
o
p
te
d
d
u
e
to
a
la
ck
o
f
su
p
p
o
rt
in
g
e
vi
d
e
n
ce
.
C
a
ff
e
in
e
ci
tr
a
te
(I
n
je
ct
io
n
an
d
o
ra
l
so
lu
ti
o
n
2
0
m
g
/m
l;
e
q
u
iv
al
e
n
t
to
1
0
m
g
ca
ff
e
in
e
b
as
e
/m
l)
N
Fo
r
tr
e
at
m
e
n
t
o
f
n
e
o
n
at
al
ap
n
o
e
a:
2
0
m
g
/k
g
lo
ad
in
g
d
o
se
,
fo
llo
w
e
d
b
y
5
–
1
0
m
g
/k
g
d
ai
ly
u
n
ti
l
re
so
lu
ti
o
n
o
f
ap
n
o
e
a
[1
].
N
Es
ti
m
at
io
n
o
f
th
e
im
p
ac
t
o
f
th
e
u
se
o
f
ca
ff
e
in
e
w
as
lim
it
e
d
b
y
a
la
ck
o
f
G
h
an
ai
an
d
at
a
o
n
th
e
in
ci
d
e
n
ce
o
f
n
e
o
n
at
al
ap
n
o
e
a.
N
C
u
rr
e
n
tl
y
th
e
re
ar
e
n
o
su
it
ab
le
p
ro
d
u
ct
s
lis
te
d
in
e
it
h
e
r
th
e
ID
P
I
p
ri
ce
g
u
id
e
o
r
th
e
W
H
O
so
u
rc
e
s
an
d
p
ri
ce
s
o
f
m
e
d
ic
in
e
s.
N
T
h
e
p
an
e
l
n
o
te
d
th
at
so
m
e
te
rt
ia
ry
ch
ild
re
n
’s
h
o
sp
it
al
s
in
G
h
an
a
ar
e
cu
rr
e
n
tl
y
im
p
o
rt
in
g
an
d
p
re
p
ar
in
g
th
e
ir
o
w
n
ca
ff
e
in
e
p
ro
d
u
ct
.
N
C
af
fe
in
e
ci
tr
at
e
w
as
ad
d
e
d
to
th
e
EM
L
w
it
h
p
la
n
s
to
id
e
n
ti
fy
a
lo
ca
l
m
an
u
fa
ct
u
re
r.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
m
e
d
.1
0
0
1
4
4
9
.t
0
0
2
PLOS Medicine | www.plosmedicine.org 4 May 2013 | Volume 10 | Issue 5 | e1001449
policy before a reliable supply of a new
drug was assured.
Artesunate was recommended as the
first-line antimalarial for severe malaria in
Africa in a 2011 update to the WHO
Malaria Treatment Guidelines [19]. The
committee accepted the evidence base
provided, and the cost implications of
introducing artesunate described above,
but were concerned that if they authorised
a switch from quinine and artemether
(which are widely available and of good
manufacturing quality), to artesunate
(where the supply may be less reliable
and with added threat of fake drugs), this
may actually increase mortality from
malaria. The committee therefore added
artesunate to the Ghana EML but de-
ferred changes to the national malaria
guidelines until a reliable supply was
established. These feasibility concerns
were discussed at a global stakeholder
meeting in November 2011 [26].
Reliable international or national sup-
pliers were also limited for dispersible zinc
tablets, dispersible amoxicillin tablets, and
caffeine citrate [11,12].
Project Outcome
Four of the five priority medicines were
approved by the expert committee for
addition to the Ghana EML: zinc sul-
phate, artesunate, dispersible amoxicillin,
and caffeine citrate. The fifth, chlorhexi-
dine, will be re-considered once the
ongoing African effectiveness studies have
been published.
Learning Points
Confident national decisions require
understanding and debate of the evidence-
base underlying global recommendations,
plus additional consideration of national
conditions and resources.
To facilitate this, global recommenda-
tions should be presented alongside trans-
parent descriptions of the evidence base,
allowing policy groups to identify where,
when, and how the interventions have
been evaluated, and any factors limiting
wider applicability.
In addition, for interventions where fea-
sibility and affordability are likely to vary
from setting to setting, the WHO could
further assist national decision-makers by
providing implementation guidance on the
assessment of health system implications,
training and education requirements, and
country level cost analyses.
As many policy questions are relevant
across sub-Saharan Africa, and national
policy makers are likely to encounter similar
problems, we strongly encourage regional
collaboration on evidence evaluation, and
sharing of information and resources. We
hope this paper will encourage further
capacity building initiatives, which facilitate
and empower countries to make more
informed decisions, choosing the interven-
tions that are right for their context, and not
implementing unproven interventions.
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